News for '-sun-pharmaceuticals'

Sensex, Nifty extend losses as West Asia tensions fuel oil price surge

Sensex, Nifty extend losses as West Asia tensions fuel oil price surge

Rediff.com22 Oct 2026

Indian equity benchmarks Sensex and Nifty extended their losses for a third consecutive session, with the Sensex declining 460.30 points and the Nifty dropping 123.70 points, primarily due to surging crude oil prices driven by escalating tensions in West Asia and weak global cues.

Indian Equities Decline for Second Day as Banking, Financial Stocks Drag

Indian Equities Decline for Second Day as Banking, Financial Stocks Drag

Rediff.com21 Oct 2026

Indian equity benchmark indices extended losses for a second consecutive session, with the Sensex dropping 143 points, driven by a sell-off in power, banking, and financial stocks, coupled with elevated crude oil prices and persistent FII selling.

Sun Pharma sees 27% profit surge in Q1FY27, driven by India and innovative medicines

Sun Pharma sees 27% profit surge in Q1FY27, driven by India and innovative medicines

Rediff.com1 Aug 2026

Sun Pharmaceutical Industries reported a 27 per cent year-on-year increase in consolidated net profit to 2,894.7 crore for Q1FY27, with revenue growing 10 per cent to 15,299.8 crore, driven by strong performance in India and innovative medicines.

Indian Equities Extend Losing Streak as Sensex Tumbles 417 Points

Indian Equities Extend Losing Streak as Sensex Tumbles 417 Points

Rediff.com3 Sep 2026

Indian benchmark equity indices extended their losing streak for a fourth consecutive day, with the Sensex tumbling 417 points due to rising crude oil prices and a significant sell-off in IT stocks, impacting overall investor sentiment.

Gautam Adani overtakes Mukesh Ambani as India's wealthiest, billionaire population hits record 391

Gautam Adani overtakes Mukesh Ambani as India's wealthiest, billionaire population hits record 391

Rediff.com23 Sep 2026

Gautam Adani and family have reclaimed the top spot on India's rich list, surpassing Mukesh Ambani, as the nation's billionaire population reached a record 391, according to the M3M Hurun India Rich List.

Sensex, Nifty pare gains on mixed global cues

Sensex, Nifty pare gains on mixed global cues

Rediff.com4 Sep 2026

The benchmark BSE Sensex rebounded by 362 points, ending a four-day losing streak, driven by strong buying in metal, private banking, and oil and gas shares, while the broader NSE Nifty saw modest gains despite paring some advances in the closing session.

Stock Markets Today: Sensex, Nifty Gain on Bank Stocks, Global Cues

Stock Markets Today: Sensex, Nifty Gain on Bank Stocks, Global Cues

Rediff.com3 Sep 2026

Indian benchmark equity indices, Sensex and Nifty, rebounded in early trade after a three-day slide, driven by strong buying in blue-chip bank stocks and a firm trend in global markets, supported by easing US bond yields and record foreign-currency deposit inflows.

Sun Pharma's $11.75 Billion Organon Acquisition: A Strategic Leap

Sun Pharma's $11.75 Billion Organon Acquisition: A Strategic Leap

Rediff.com27 Apr 2026

Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.

Outbound M&A by Indian firms robust despite West Asia tensions: HSBC's Sharma

Outbound M&A by Indian firms robust despite West Asia tensions: HSBC's Sharma

Rediff.com10 Jul 2026

Indian companies' overseas expansion plans are holding strong despite geopolitical tensions in West Asia, driven by structural factors like supply-chain diversification, free trade agreements, and market expansion, according to Ajay Sharma, managing director and head of banking at HSBC India.

Sensex Rises Over 700 Points, Nifty Crosses 23,600 Amid Positive Market Sentiment

Sensex Rises Over 700 Points, Nifty Crosses 23,600 Amid Positive Market Sentiment

Rediff.com14 May 2026

Indian benchmark equity indices, Sensex and Nifty, saw gains in early trade, driven by strong performance in banking shares and positive sentiment from Asian markets, alongside optimism surrounding the ongoing US-China Summit.

Indian Pharma Bets Beyond US Generics

Indian Pharma Bets Beyond US Generics

Rediff.com26 Jun 2026

Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.

Sun Pharma's Organon deal: Strategic entry into new segments, but integration challenges loom

Sun Pharma's Organon deal: Strategic entry into new segments, but integration challenges loom

Rediff.com5 May 2026

Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.

Sun Pharma US generics biz remains under pressure

Sun Pharma US generics biz remains under pressure

Rediff.com23 May 2026

Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.

Sensex gains nearly 790 points, driven by telecom and banking sector buying

Sensex gains nearly 790 points, driven by telecom and banking sector buying

Rediff.com14 May 2026

Indian stock markets saw a significant rebound, with the Sensex jumping nearly 790 points, primarily fuelled by strong buying interest in telecom, pharma, and private banking shares, despite a volatile trading session and a weakening rupee.

Indian Investments in US Rise, Create American Jobs: Official

Indian Investments in US Rise, Create American Jobs: Official

Rediff.com5 May 2026

Indian foreign direct investment (FDI) in the United States has reached approximately USD 16.4 billion, supporting around 70,800 jobs and contributing significantly to research and development, according to US Deputy Undersecretary Brandon Remington.

Indian Pharma Firms Deepen US Investment in Specialty Drugs Amidst Generic Pressure

Indian Pharma Firms Deepen US Investment in Specialty Drugs Amidst Generic Pressure

Rediff.com2 Jun 2026

Indian pharmaceutical companies are strategically increasing investments in the US market, focusing on specialty drugs, complex generics, respiratory products, and local manufacturing, despite a nearly 10 per cent fall in exports to the US in FY26 due to pricing pressure and competition in traditional generics.

Inflation, weak rupee drag Indian markets lower; fuel price hike adds to concerns

Inflation, weak rupee drag Indian markets lower; fuel price hike adds to concerns

Rediff.com15 May 2026

Indian benchmark equity indices, Sensex and Nifty, closed lower due to investor caution over rising bond yields, a weaker rupee, and fresh fuel price hikes, which have revived inflation concerns.

Indian Equities Bounce Back: Sensex Jumps 639 Pts, Nifty Up 194 Pts

Indian Equities Bounce Back: Sensex Jumps 639 Pts, Nifty Up 194 Pts

Rediff.com27 Apr 2026

Indian benchmark stock indices Sensex and Nifty rebounded nearly 1 per cent, snapping a three-day decline, driven by rallies in Reliance Industries and Sun Pharma, alongside positive global market trends and easing geopolitical tensions.

What Dilip Shanghvi said on Sun Pharma's Organon Buy

What Dilip Shanghvi said on Sun Pharma's Organon Buy

Rediff.com27 Apr 2026

Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the USD 11.75 billion acquisition of US-based Organon & Co as both a "happy" and "bit anxious" moment, acknowledging the significant debt required to fund the large transaction.

Vikash Lohia Tops Hurun Successors List

Vikash Lohia Tops Hurun Successors List

Rediff.com23 Apr 2026

Karan Adani of Adani Ports & Special Economic Zone emerged as the top absolute value creator, adding Rs 2.67 trillion as the company's mcap rose from Rs 42,149 crore in March 2020 to Rs 3.09 trillion in March 2026 (7.3x) -- the largest rupee addition on the list.

Sensex Crashes 1,400 Points, Nifty Near 22,250: Trump-Iran Tensions Trigger Market Selloff

Sensex Crashes 1,400 Points, Nifty Near 22,250: Trump-Iran Tensions Trigger Market Selloff

Rediff.com2 Apr 2026

Sensex plunges over 1,400 points and Nifty slips near 22,250 amid Trump's Iran threat, rising crude oil prices, and FII selling. Here are the key reasons behind today's market crash.

Stock Market Today: Sensex, Nifty50 decline 2% on rising tensions in West Asia

Stock Market Today: Sensex, Nifty50 decline 2% on rising tensions in West Asia

Rediff.com2 Apr 2026

Indian equities on Dalal Street saw volatility as global market trends and fresh tariff concerns linked to Donald Trump impacted investor sentiment. Track Sensex, Nifty50 movement and key market drivers for April 2, 2026.

Sensex gains 398 points on easing of geopolitical tensions

Sensex gains 398 points on easing of geopolitical tensions

Rediff.com22 Jan 2026

Benchmark equity indices Sensex and Nifty rebounded on Thursday after three sessions of losses, tracking gains in global markets after US President Donald Trump struck a conciliatory tone on Greenland. In a volatile session, the 30-share BSE Sensex climbed 397.74 points, or 0.49 per cent, to close at 82,307.37.

Sun Pharmaceutical's vital signs: A strong dose of valuation multiples

Sun Pharmaceutical's vital signs: A strong dose of valuation multiples

Rediff.com13 Nov 2023

Bolstered by an impressive performance in the global specialty business and outstanding results in the Indian market, Sun Pharmaceutical Industries, the largest pharmaceutical (pharma) company in the country, showcased a strong performance in the July-September quarter (second quarter, or Q2) of 2023-24 (FY24).

Sensex, Nifty Recover to Close Higher Amidst Rupee Rebound

Sensex, Nifty Recover to Close Higher Amidst Rupee Rebound

Rediff.com2 Apr 2026

Indian stock markets recovered from early losses to close higher, driven by value buying in IT and banking shares and a rebound in the rupee.

Sensex closed 283 points higher on buying in bank, metal shares

Sensex closed 283 points higher on buying in bank, metal shares

Rediff.com18 Feb 2026

Benchmark equity indices Sensex and Nifty extended their gains for the third straight session on Wednesday, driven by last-hour buying in bank, metal, and FMCG shares.

Sensex reclaims 84K-mark; Nifty ends up 174 points

Sensex reclaims 84K-mark; Nifty ends up 174 points

Rediff.com9 Feb 2026

Benchmark equity indices Sensex and Nifty extended their gains for the second straight session on Monday, driven by optimism over the India-US trade deal and robust buying in public sector banks, consumer durables, and realty stocks.

Stock Market Today: Sensex, Nifty50 React to Global Cues and Trump Tariff Concerns

Stock Market Today: Sensex, Nifty50 React to Global Cues and Trump Tariff Concerns

Rediff.com24 Feb 2026

Indian equities on Dalal Street saw volatility as global market trends and fresh tariff concerns linked to Donald Trump impacted investor sentiment. Track Sensex, Nifty50 movement and key market drivers for Feb 24, 2026.

Sensex Plunges 1069 Points on IT Selloff, Global Trade Worries

Sensex Plunges 1069 Points on IT Selloff, Global Trade Worries

Rediff.com24 Feb 2026

Equity benchmark indices Sensex and Nifty experienced a significant decline, primarily driven by a selloff in IT stocks due to concerns about AI disruption and renewed worries over global trade.

Sensex, Nifty close almost unchanged in choppy trade

Sensex, Nifty close almost unchanged in choppy trade

Rediff.com11 Feb 2026

Benchmark stock indices Sensex and Nifty closed on a flat note in a choppy session on Wednesday as gains in PSU banks and auto shares were offset by losses in IT stocks.

AI is fast becoming central to how drugs will be discovered

AI is fast becoming central to how drugs will be discovered

Rediff.com25 Feb 2026

Artificial intelligence (AI) is no longer a side conversation for Indian pharma. It is fast becoming central to how drugs will be discovered, made, and supplied. Along with that shift comes a sharper focus on innovation, on the one hand, and quality and trust, on the other.

Sensex up 174 points on gains in bank, IT stocks

Sensex up 174 points on gains in bank, IT stocks

Rediff.com17 Feb 2026

Stock markets closed higher for the second straight session on Tuesday, driven by gains in bank, IT and capital goods shares.

New launches to keep growth momentum healthy for Sun Pharma stock

New launches to keep growth momentum healthy for Sun Pharma stock

Rediff.com13 Feb 2026

A strong third-quarter (October-December/Q3) performance for 2025-26 (FY26) has helped the stock of India's largest listed pharmaceutical (pharma) company, Sun Pharmaceutical Industries, gain about 7 per cent since the start of February.

Semaglutide Ruling Sparks Generic Pharma Boom

Semaglutide Ruling Sparks Generic Pharma Boom

Rediff.com24 Mar 2026

At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.

Hungry IPOs Carve A Heft Slice Of Mutual Funds

Hungry IPOs Carve A Heft Slice Of Mutual Funds

Rediff.com22 Dec 2025

In November, six primary market issuances accounted for more than 13,000 crore of net equity investments by MFs.

Sensex down 275 points on fag-end selling

Sensex down 275 points on fag-end selling

Rediff.com10 Dec 2025

Among the Sensex constituents, Eternal, Trent, Bharti Airtel, Infosys, Tech Mahindra, UltraTech Cement, ICICI Bank, HDFC Bank, Bajaj Finance, Tata Consultancy Services, Bharat Electronics Ltd, Larsen & Toubro and Tata Motors Passenger Vehicles were the laggards. However, Tata Steel, Sun Pharmaceuticals, ITC, NTPC, Reliance Industries, HCL Technologies, PowerGrid, and Asian Paints were among the gainers.

Sensex jumps 427 points on buying in metal, auto shares

Sensex jumps 427 points on buying in metal, auto shares

Rediff.com11 Dec 2025

Among the Sensex constituents, Eternal, Tata Steel, Kotak Mahindra Bank, UltraTech Cement, Maruti Suzuki India, Sun Pharmaceuticals, Tech Mahindra, HDFC Bank, Tata Motors Passenger Vehicles, Infosys, Trent, Mahindra & Mahindra, Reliance Industries and HCL Technologies were the gainers. However, Asian Paints, Bharti Airtel, Bajaj Finance, PowerGrid, Axis Bank, ICICI Bank and Titan were among the laggards.

Indian pharma companies see sharp drop in adverse USFDA findings in 2025

Indian pharma companies see sharp drop in adverse USFDA findings in 2025

Rediff.com8 Jan 2026

The US Food and Drug Administration (USFDA) recorded a significant decline in serious regulatory findings at Indian drug manufacturing facilities between January and December 2025. Data reveals that 'official action indicated' (OAI) cases - the most severe classification - nearly halved over the past year.

Sensex, Nifty settle with modest gains

Sensex, Nifty settle with modest gains

Rediff.com14 Nov 2025

From the Sensex pack, Eternal, Bharat Electronics Ltd, Trent, Axis Bank, State Bank of India, Bajaj Finance, Sun Pharmaceuticals, Asian Paints, Adani Ports, Hindustan Unilever, Reliance Industries, ITC, PowerGrid, Tata Motors Ltd's Commercial Vehicles business, and Bajaj Finserv were the gainers. Infosys, Tata Motors Passenger Vehicles, Tata Steel, ICICI Bank, Tech Mahindra, Titan, UltraTech Cement, Maruti Suzuki India, and Larsen & Toubro were the laggards.

India's Billionaire Club Shrinks in 2025

India's Billionaire Club Shrinks in 2025

Rediff.com8 Jan 2026

The 2025 contraction marks the steepest decline in both the number of billionaire promoters and their aggregate wealth since 2012.